Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs

Table 2

24 h glycemic profiles.

	Baseline	4 weeks after the treatment
24 h MBG (mmol/L)			0.001
MAGE (mmol/L)			0.048
TIR (%)			0.002
TAR (%)	20.66 (6.95, 40.80)	9.38 (0.00, 18.49)	0.001
TBR (%)	0.00 (0.00, 0.00)	0.00 (0.00, 1.39)	0.796
AUC3.9-10 (mmol/Ld)			0.002
(mmol/Ld)	11.35 (2.64, 51.54)	5.78 (0.00, 20.51)	0.003
(mmol/Ld)	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)	0.959
HBGL			0.000
LBGL	0.68 (0.00, 2.23)	1.18 (0.25, 2.68)	0.223
GMI (mmol/mol)			0.001

Data were shown as or median (first quartile, third quartile). Baseline vs. 4 weeks after the treatment: . 24 h MBG: 24-hour mean blood glucose; MAGE: 24-hour mean amplitude of glycemic excursion; TIR: time-in-range (3.9-10 mmol/L); TAR: time-above-target range (>10 mmol/L); TBR: time-below-target ranges (<3.9 mmol/L); AUC3.9-10: the incremental area under the curve of the glucose level between 3.9 and 10 mmol/L; : the incremental area under the curve of the glucose level more than 10 mmol/L; : the incremental area under the curve of the glucose level less than 3.9 mmol/L; HBGI: high blood glucose index; LBGI: low blood glucose index; GMI: glucose management indicator.